CUE-102 in Recurrent Glioblastoma

Summary

The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)

Timeline

Start

2025-07-30

Primary completion

2027-01-31

Completion

2028-01-31

Drugs

Indications